

**Amendments to the Claims:**

*This listing of claims will replace all prior versions, and listings, of claims in the application:*

1. (Currently Amended) A human anti-idiotypic antibody Fab- or scFv- fragment, which is ~~capable of mimicking~~ mimics Her-2/neu tumor associated antigen, and which comprises CDR1H of sequence SYAMS (SEQ ID No: 15), CDR1L of sequence QGDSLRSYYAS (SEQ ID No: 16), CDR2H of sequence SGGTYADSVKG (SEQ ID No: 17), CDR2L of sequence GKNNRPS (SEQ ID No: 18), and (i) CDR3H of sequence SEQ ID No: 3 and CDR3L of sequence SEQ ID No: 4, or (ii) CDR3H of sequence SEQ ID No: 5 and CDR3L of sequence SEQ ID No: 6, wherein said fragment is directed against trastuzumab F(ab')<sub>2</sub>.

2. (Original) The fragment of claim 1, that comprises a sequence SEQ ID No: 3 in the CDR3 region of the VH domain and a sequence SEQ ID No: 4 in the CDR3 region of the VL domain.

3. (Original) The fragment of claim 1, that comprises a sequence SEQ ID No: 5 in the CDR3 region of the VH domain and a sequence SEQ ID No: 6 in the CDR3 region of the VL domain.

4. (Cancelled).

5. (Previously Presented) The fragment of claim 2, which comprises the amino acid sequence SEQ ID No: 1, this fragment being designated scFv40.

6. (Previously Presented) The fragment of claim 3, which comprises the amino acid sequence SEQ ID No: 2, this fragment being designated scFv69.

7. (Previously Presented) A multimer of the antibody fragment defined in claim 1.

8. (Previously Presented) A pharmaceutical composition comprising an antibody fragment according to claim 1, or a multimer of the antibody fragment, in association with a pharmaceutically acceptable carrier.

9-15. (Cancelled).

16. (New) A human anti-idiotypic antibody Fab- or ScFv- fragment, which mimicks Her-2/neu tumor associated antigen, and which comprises CDR1H of sequence SYAMS (SEQ ID No: 15), CDR1L of sequence QGDSLRSYYAS (SEQ ID No: 16), CDR2H of sequence SGGTTYADSVKG (SEQ ID No: 17), CDR2L of sequence GKNNRPS (SEQ ID No: 18), and CDR3H of sequence SEQ ID No: 3 and CDR3L of sequence SEQ ID No: 4, wherein said fragment comprises the amino acid sequence SEQ ID No: 1, this fragment being designated scFv40.

17. (New) A multimer of the antibody fragment defined in claim 16.

18. (New) A pharmaceutical composition comprising an antibody fragment according to claim 16, or a multimer of the antibody fragment, in association with a pharmaceutically acceptable carrier.

19. (New) A human anti-idiotypic antibody Fab- or ScFv- fragment, which mimicks Her-2/neu tumor associated antigen, and which comprises CDR1H of sequence SYAMS (SEQ ID No: 15), CDR1L of sequence QGDSLRSYYAS (SEQ ID No: 16), CDR2H of sequence SGGTTYADSVKG (SEQ ID No: 17), CDR2L of sequence GKNNRPS (SEQ ID No: 18), and CDR3H of sequence SEQ ID No: 5 and CDR3L of

sequence SEQ ID No: 6, wherein said fragment comprises the amino acid sequence SEQ ID No: 2, this fragment being designated scFv69.

20. (New) A multimer of the antibody fragment defined in claim 19.

21. (New) A pharmaceutical composition comprising an antibody fragment according to claim 19, or a multimer of the antibody fragment, in association with a pharmaceutically acceptable carrier.